In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus

Coronary Artery Disease

Volumn 19, Issue 4, 2008, Pages 279-284

  Schlitt, Axel ^a   Rupprecht, Hans J ^b   Reindl, Iris ^a   Schubert, Sebastian ^a   Hauroeder, Baerbel ^d   Carter, Justin M ^a   Peetz, Dirk ^e   Kropff, Stefan S ^c   Maegdefessel, Lars ^a   Russ, Martin ^a   Schmidt, Hendrik ^a   Ebelt, Henning ^a   Werdan, Karl ^a   Buerke, Michael ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b GPR Clinic   (Germany)

^c Glaxo Smith Kline   (Germany)

^d Deutsche Bundeswehr   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Anticoagulation; Fondaparinux; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN; FONDAPARINUX; HEPARIN; FIBRINOLYTIC AGENT; POLYSACCHARIDE;

ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CELL COUNT; CONTROLLED STUDY; ELECTRON MICROSCOPY; ERYTHROCYTE; FIBRIN DEPOSITION; HEART CATHETER; HEART CATHETERIZATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; INTRACARDIAC THROMBOSIS; MALE; NORMAL HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHLEBOTOMY; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS PREVENTION; COMPARATIVE STUDY; DRUG EFFECT; THROMBOSIS;

ENOXAPARIN; FIBRINOLYTIC AGENTS; HEART CATHETERIZATION; HEPARIN; HUMANS; MALE; MICROSCOPY, ELECTRON; POLYSACCHARIDES; THROMBOSIS;

EID: 54749095579     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328300426b     Document Type: Article

References (18)

1. Herbert JM, Herault JP, Bernat A, van Amsterdam RG, Lormeau JC, Petitou M, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91:4197-4205.
2. Turpie AG, Gallus AS, Hoek JA; Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344:619-625.
3. Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert JM, van Boeckel CA, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inihibitors. Cardiovasc Drug Rev 2002; 20:37-45.
4. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695-1702.
5. Simoons ML, Bobbink IW, Boland J, Gardien M, Klootwijk P, Lensing AW, et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 2004; 43:2183-2190.
6. Coussement PK, Bassand JP, Convens C, Vrolix M, Boland J, Grollier G, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study. Eur Heart J 2001; 22:1716-1724.
7. Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 2005; 111: 1390-1397.
8. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354:1464-1476.
9. Buerke M, Pittroff W, Meyer J, Darius H. Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 1995; 130:465-472.
10. Harding SA, Din JN, Sarma J, Josephs DH, Fox KA, Newby DE. Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin. Heart 2006; 92:1635-1638.
11. Schneider DJ, Keating F, Sobel BE. Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibatide on thrombin-induced platelet activation. Coron Artery Dis 2006; 17:471-476.
12. Gerotziafas GT, Chakroun T, Samama MM, Elalamy I. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. Thromb Haemost 2004; 92:1296-1302.
13. Schlitt A, Hamilton K, Maegdefessel L, Dahm M, Theis C, Eichler M, et al. Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in-vitro study. J Heart Valve Dis 2006; 15:809-814.
14. Schlitt A, Hauroeder B, Buerke M, Peetz D, Victor A, Hundt F, et al. Effects of combined therapy of clopidogrel and aspirin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. Thromb Res 2002; 107:39-43.
15. Schlitt A, Buerke M, Hauroeder B, Peetz D, Hundt F, Bickel C, et al. Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. Thromb Haemost 2003; 90:245-251.
16. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82:165-174.
17. The OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 Randomized Trial. J Am Med Assoc 2006; 295:1519-1530. 18 Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203:493-495.
18. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203:493-495.